On February 26, 2021 Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, reported the closing of a $120 million Series B financing (Press release, Artiva Biotherapeutics, FEB 26, 2021, View Source [SID1234580588]). New investor Venrock Healthcare Capital Partners led the financing. Other new investors participating in the financing included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel Company), Wellington Management Company, and an undisclosed leading global investment firm. Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX: 005250), also participated in the financing. Artiva plans to use the proceeds from the financing to advance its NK cell therapy development programs and expand ongoing research and development activities.
"The quality and support of the investor groups participating in this financing further validates the promise of our manufacturing first strategy, the potential of our NK cell platform, and our goal to provide safe, effective, and truly off-the-shelf cell therapy treatments that are immediately accessible to cancer patients," said Fred Aslan, M.D., CEO of Artiva. "I would also like to welcome Bong Koh to our board of directors and look forward to drawing upon his expertise as we continue to advance our clinical and other development activities."
"Artiva is a promising company with differentiated technology, strong manufacturing capabilities and a talented management team," said Bong Koh, M.D., with Venrock Healthcare Capital Partners. "I look forward to working closely with Artiva’s board and management during this exciting period of growth for the company."
Artiva’s cell therapies are designed to leverage the innate anti-tumor biology and safety features of NK cells. The therapies are optimized for targeted anti-cancer activity through CARs, or ADCC enhancement through therapeutic antibody or innate-cell engager combination therapy. Artiva’s manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies, and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity.